- Morphic is pursuing a multi-billion opportunity of replacing biologics modulating integrins with small molecules.
- The company is founded by the individual who discovered integrins and has built a unique technology platform to design selective oral therapies for integrins.
- Morphic recently reported promising phase 1 data for its lead asset, MORF-057 establishing safety.
- Now the company is bringing their lead asset into phase 2 trials; however, with the concentration risk and current valuation, Morphic is a stock worth monitoring as the trial progresses.
For further details see:
Morphic: Pioneering Integrin Medicines